Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Child's Nervous System
Published in: Child's Nervous System 1/2011

01-01-2011 | Letter to the Editor

MGMT promoter methylation in pediatric high-grade gliomas

Authors: Matteo Fassan, Evelyne Tassone, Maurizio Onisto, Giorgio Perilongo, Domenico D’Avella, Marina Paola Gardiman

Published in: Child's Nervous System | Issue 1/2011

Login to get access

Excerpt

Dear Editor: …
Literature
1.
Buttarelli FR, Massimino M, Antonelli M, Lauriola L, Nozza P, Donofrio V, Arcella A, Oliva MA, Di Rocco C, Giangaspero F (2010) Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas. Childs Nerv Syst 26:1051–1056CrossRefPubMed
2.
Srivastava A, Jain A, Jha P, Suri V, Sharma MC, Mallick S, Puri T, Gupta DK, Gupta A, Sarkar C (2010) MGMT gene promoter methylation in pediatric glioblastomas. Childs Nerv Syst. doi:10.​1007/​s00381-010-1214-y
3.
Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 48:403–407CrossRefPubMed
4.
Schlosser S, Wagner S, Mühlisch J, Hasselblatt M, Gerss J, Wolff JE, Frühwald MC (2010) MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience. Pediatr Blood Cancer 54:228–237PubMed
5.
Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermanni M (2006) Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 24:4746–4753CrossRefPubMed
Metadata
Title
MGMT promoter methylation in pediatric high-grade gliomas
Authors
Matteo Fassan
Evelyne Tassone
Maurizio Onisto
Giorgio Perilongo
Domenico D’Avella
Marina Paola Gardiman
Publication date
01-01-2011
Publisher
Springer-Verlag
Published in
Child's Nervous System / Issue 1/2011
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-010-1313-9

Other articles of this Issue 1/2011

Child's Nervous System 1/2011 Go to the issue

Original Paper

Huge hydrocephalus: definition, management, and complications

Case Illustration

Depressed skull fracture by a three-pin head holder: a case illustration

Case Report

Multiple primary cranio-spinal tumours in a 13-year-old female with neurofibromatosis type 2 management strategy

Original Paper

Increased expression of l-amino acid transporters in balloon cells of tuberous sclerosis

Original Paper

The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis

Original Paper

Endoscopic third ventriculostomy versus ventriculoperitoneal shunt in the treatment of obstructive hydrocephalus due to posterior fossa tumors in children